NLRP3 and diffuse large B-cell lymphoma: In either in vitro or in vivo experiments, administration of NLRP3 inhibitors caused amelioration of the disease burden in AML, DLBCL, GvHD, multiple myeloma, and sickle cell anemia [25,36,40,61,67].